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Abstract
In this review, we examine the evidence for mammographic density
as an independent risk factor for breast cancer, describe the risk
prediction models that have incorporated density, and discuss the
current and future implications of using mammographic density in
clinical practice. Mammographic density is a consistent and strong
risk factor for breast cancer in several populations and across age
at mammogram. Recently, this risk factor has been added to
existing breast cancer risk prediction models, increasing the
discriminatory accuracy with its inclusion, albeit slightly. With
validation, these models may replace the existing Gail model for
clinical risk assessment. However, absolute risk estimates resulting
from these improved models are still limited in their ability to
characterize an individual’s probability of developing cancer.
Promising new measures of mammographic density, including
volumetric density, which can be standardized using full-field digital
mammography, will likely result in a stronger risk factor and
improve accuracy of risk prediction models.
Introduction
Variation in the radiographic appearance of the breast
reflects differences in tissue composition [1]: darker regions
indicate fat tissue and lighter regions represent dense tissue,
primarily fibroglandular tissue consisting of the functional
elements or parenchyma, and supporting elements or stroma
[2]. The proportion of the lighter or dense regions on the
mammogram, characterized as mammographic density (MD),
has consistently been one of the strongest risk factors for
breast cancer, with risk estimates that are three- to five-fold
greater for women in the highest quartile of density than for
women of similar age in the lowest quartile [3]. As increased
MD is common in the population, with 26% to 32% of
women in the general population having densities of 50% or
greater (Table 1), 16% to 32% of breast cancers may be
attributed to this trait [4,5], with an even larger estimated
proportion among premenopausal women [6].
The magnitude and consistency of the MD and breast cancer
association place its importance as a breast cancer risk
factor alongside age, the presence of atypia on a breast
biopsy, or carrying a highly penetrant breast cancer suscepti-
bility gene (for example, BRCA1 and BRCA2) [7], the latter
two which are rare in the population and responsible for only
a small proportion of breast cancer. However, until recently,
MD has not been used in clinical risk prediction models or
clinical decision making. The purpose of this review is to
summarize the evidence and strength of MD as a risk factor,
review the studies that have evaluated MD in risk prediction,
and discuss the implications of incorporating this trait into
clinical practice for improving breast cancer risk assessment.
Part I. Mammographic density as a risk factor
for breast cancer
The association between MD and breast cancer has been
investigated in more than 50 studies over the last three
decades. These studies have varied in their approaches to
the measurement of MD (reviewed in Table 2), study designs,
and populations. The majority (n = 42) of these studies were
recently reviewed [3] and incorporated into a meta-analysis.
They illustrate a high prevalence of increased density in the
general population, whether estimated by percentage density
(26% to 32% of women had 50% or more), parenchymal
pattern (21% to 55% of women had the P2 or DY pattern), or
Breast Imaging Reporting and Data System (BI-RADS)
density (31% to 43% had a BI-RADS of 3 or 4) (Table 1).
Also, the results show that there exists a strong dose-
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response association between MD and breast cancer
regardless of the type of assessment (quantitative or qualita-
tive), the population (symptomatic or asymptomatic), or
whether the density assessment was made on a negative
mammogram years prior to the cancer diagnosis (incidence
studies) or on the contralateral mammogram at the time of the
breast cancer diagnosis (prevalence studies) (Table 1).
However, the strongest overall associations are seen among
the quantitative percentage density phenotype estimated
subjectively by a radiologist or using semi-objective methods
(thresholding and the planimetry or tracing methods) [8].
Other aspects of the mammogram which have been less
frequently examined with risk include the absolute area of
density [4,9-14], types of densities (nodular versus
homogeneous) [15,16], and computer-automated measures
of characteristics of the underlying mammogram image or
pixel distribution [3]. To date, these have not consistently
shown stronger estimates with breast cancer than the
quantitative MD measure [3]. That density assessed at a
variety of institutions with mammograms over differing time
Table 1
Combined relative risks for breast cancer associated with different classifications of mammographic density, study designs, and
study populations from meta-analysis [3]
General population Symptomatic population
Incidence studies Prevalence studies
Cases/ RR Cases/ RR Cases/ RR 
Classification Non-casesa (95% CI) Non-casesa (95% CI) Non-casesa (95% CI)
Wolfe parenchymal pattern 2,664 /23,469b 2,169 /32,184b 1,857/25,394b
N1 181/3,613 1.0 557/15,731 1.0 428/3,318 1.0
P1 525/6,682 1.8 (1.4, 2.2) 519/9,684 1.3 (1.0, 1.5) 315/5,031 1.0 (0.77, 1.3)
P2 1,162/10,433 3.1 (2.5, 3.7) 660/4,369 2.0 (1.3, 3.0) 526/5,128 1.5 (0.91, 2.4)
DY 246/2,309 4.0 (2.5, 6.3) 294/2,216 2.4 (2.0, 3.0) 400/4,976 1.7 (1.0, 2.8)
Percentage mammographic density  4,508/8,342b 2,219/4,063b 160/160b
<5%
1,194/1,744c 1.0
643/1,182c 1.0
35/84c 1.0
5%-24% 1.8 (1.5, 2.2) 1.4 (1.1, 1.8)
25%-49% 1,049/1,045 2.1 (1.7, 2.6) 589/835 2.2 (1.8, 2.8) 66/35 5.5 (2.8-11)
50%-74%
1,211/999
2.9 (2.5, 3.4) 438/665 2.9 (2.3, 3.8) 34/23 4.8 (2.2-11)
75%+ 4.6 (3.6, 5.9) 190/282 3.7 (2.7, 5.0) 25/18 4.3 (1.8-10)
BI-RADS 1,992/104,663b Vacek Ziv  397/1,589b
and  et al. 
Geller [57]
[30]
Fatty 62/7,550 1.0 0.3
(Ref) (0.2, 0.4) 20/134 1.0
Scattered density 950/52,379 2.2 1.0
(1.6, 3.0) (Ref) 216/957 1.6 (0.9, 2.8)
Heterogeneous density 783/36,564 3.0 1.3
(2.2, (1.1, 
4.1) 1.5) 117/407 2.3 (1.3, 4.3)
Extremely dense 197/8,170 4.0 20.1
(2.8, (1.6, 
5.7) 2.8) 44/91 4.5 (1.9, 10.6)
aCases and controls from individual categories may not add to the overall number of cases and controls used in the meta-analysis since categories
from individual studies did not always coincide with those presented in the meta-analysis. Only numbers of cases and controls from studies with
these categories are presented and used for the calculation of prevalence. bTotal cases and noncases used in meta-analysis by McCormack and
colleagues [3] for each classification and study type. cWhen possible, categories were combined to provide the maximum contribution of cases
and controls from individual studies. BI-RADS, Breast Imaging Reporting and Data System; CI, confidence interval; Ref, reference; RR, relative risk.Page 3 of 9
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.periods showed highly consistent results illustrates that the
MD and breast cancer association is not greatly influenced by
mammogram quality, estimation method, or year the mammo-
gram was performed.
MD is correlated with several breast cancer risk factors; the
strongest associations are seen with body mass index (BMI)
and age [4,8]. Importantly, though, MD is an independent risk
factor for breast cancer, illustrated in the majority of studies
by its robust association with breast cancer after adjustment
for these and other risk factors for breast cancer [4,8]. In fact,
recent studies of percentage MD and breast cancer
illustrated that failure to adjust for BMI resulted in under-
estimation of the effect of MD on risk [17,18]. Thus, the
adjustments for BMI and age are important for accurately
estimating the risk associated with MD.
Modification of association by risk factors and ethnicity
Few studies have examined potential modifying effects of risk
factors on the MD and breast cancer association. Hormone
replacement therapy (HRT), especially combination therapy,
consistently shows a strong positive association with MD
[19] and should be considered in analyses of MD with risk,
but studies have not seen a modification of the MD and risk
association by HRT use [18,20]. A stronger association of
MD and risk has been seen among women with breast
cancer in a first-degree relative [21-24]; but among carriers
with a BRCA1 or BRCA2 mutation, relative risks were similar
to those of non-carriers [25]. The suggestion of stronger
associations among women with high BMI [20] has been
reported, as well as findings that the higher risk associated
with low parity is stronger among women with high MD
[20,26]. No difference of association has been seen by
alcohol use [27]. To date, there is little consistent evidence
that the risk associated with MD varies according to other risk
factors for breast cancer.
The MD and breast cancer association is not limited to older
or younger women of mammogram age. But there is currently
no consensus as to whether the association is stronger
among one age or menopausal group. Some studies [4,12,
18,28] observed stronger risk estimates among postmeno-
pausal women (or those over age 50), whereas others [6,29]
found stronger associations in younger or premenopausal
women or neither group [30]. The recent meta-analysis
suggested stronger relative risks at older ages that were
limited to the 25% to 49% category (versus less than 5%)
but no consistent increase across all categories [3].
Importantly, a larger proportion of premenopausal women
have dense breasts (greater than 50% dense), with estimates
of 37% among premenopausal women compared with 12%
among postmenopausal women. Even without significant
differences in association by menopausal status, the
attributable risk is much higher in younger women (26%) than
in older women (7%) [6]. This underscores the importance of
MD for potential risk prediction in younger women.
Unfortunately, due to the nature of this trait’s dependence on
a mammogram for estimation, the significance of MD in young
women below mammogram age is unknown.
In addition, MD has been seen to be associated with
increased risk across several ethnic groups. Studies of
Caucasians, African-Americans, and Asian-Americans [12,14,
31] have all shown increased risk with percentage or area
density. However, the magnitude of association has been
weaker [14,31] or inconsistent in the Asian and Asian-
American populations [12,20,32], questioning the
importance of this predictor in the Asian population. In fact,
some have suggested that absolute area of density is a better
measure of breast cancer risk than percentage density in the
Asian population due to their distinct physical proportions
[33]. In general, MD assessed as the parenchymal pattern,
percentage density, and absolute area of density appears to
be a strong risk factor in a number of populations.
More than masking bias
The relationship between MD and breast cancer is thought to
be multifactorial, and in early studies, the main explanation
was thought to be due to ‘masking bias’ [34]. In breasts with
extensive MD, cancers may be masked because they have
the same x-ray attenuation properties as fibroglandular tissue.
At an initial mammogram, then, cancers in dense breasts
would often escape detection and could manifest themselves
shortly thereafter. Therefore, the sole inclusion of incident
cases arising shortly after a negative screening examination
would erroneously give the impression of increased breast
cancer risk in women with extensive MD. The MD and breast
cancer association was expected to disappear with longer
follow-up and repeated screening. But two large cohort
studies from the 1990s [4,28] challenged the ‘masking bias’
hypothesis, finding increased breast cancer risks for at least
7 to 10 years after a screening examination. This is also
confirmed in the latest large-scale studies on MD and breast
cancer risk [6,13,35]. Furthermore, although relative risks for
breast cancer are higher when studying incident cases
diagnosed relatively shortly after a negative examination than
when studying prevalent cases, risk is still strong among
prevalent cases [36-38]. Similarly, although relative risks are
higher when studying interval cancers than when studying
screen-detected cancers, studies of screen-detected
cancers still demonstrate a strong association [6,37]. This
was recently illustrated in three nested case-control studies
by Boyd and colleagues [6], who found that compared with
women  with density in less than 10% of the mammogram,
women with more than 75% density had an increased risk of
breast cancer (odds ratio [OR] = 4.7; 95% confidence interval
[CI]: 3.0, 7.4), whether detected by screening (OR = 3.5; 95%
CI: 2.0, 6.2) or detected within 12 months of a negative
screening examination (OR = 17.8; 95% CI: 4.8, 65.9).
In summary, the MD and breast cancer association is robust
irrespective of measurement of MD, strong in magnitude, not
Breast Cancer Research    Vol 9 No 6 Vachon et al.
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other risk factors, and generalizable to several populations,
including both premenopausal and postmenopausal women.
Due to the high prevalence of increased MD in the
population, this risk factor could explain a large proportion of
breast cancers as well as provide additional clinical
information for breast cancer risk prediction. Translating the
estimates of risk corresponding to different levels of MD into
a model that could be used as an assessment tool for breast
cancer risk prediction is a logical consideration and is
explored in the following section.
Part II. Mammographic density in risk
prediction
Evaluation of risk prediction models
The extant literature on MD and breast cancer is based
almost entirely on the OR or relative risk as the measure of
association. However, these reports do not adequately
describe the ability of a risk factor to discriminate between
individuals who are at higher and lower risk of an outcome
[39]. To assess the predictive quality of a risk factor, such as
MD, other measures of association are required. The most
commonly used measure of discriminatory power is often
referred to as the C-statistic. This quantity is the concordance
statistic that measures the agreement between predicted and
observed outcomes. For diagnostic tests, this is equivalent to
the area under the receiver operating characteristic (ROC)
curve. A mathematically identical measure can be computed
for outcomes that have a time-to-event component. It is
computed by forming all possible pairs of subjects whose
outcomes are distinct (for example, one case and one
control) and by tallying the number of pairs in which the
subject with higher observed risk also has a higher risk
predicted by the risk factor, or risk model, of interest [40].
This C-statistic ranges from 0.5 to 1.0. Values of 0.5 indicate
that the risk predictions are no better than a coin toss at
discriminating a high-risk from a low-risk individual, and values
of 1.0 show that the risk prediction can make a perfect
discrimination.
There is a strong correspondence between the OR and the
C-statistic [41]. Pepe and colleagues [39] outline the
relationship between the two measures that are used to
construct an ROC curve. From these relationships, it is
possible to compute the C-statistic that corresponds to the
OR from a binary risk factor (Figure 1). The curve in Figure 1
illustrates that a binary risk factor with an OR of 2.0 has a
very modest discriminatory capacity. Although this correspon-
dence is exact only for binary risk factors, it illustrates the
magnitude of OR that is required in order for risk predictions
that are highly concordant with actual outcomes. To use this
correspondence to illustrate the expected degree of
concordance that would correspond to a model based on
MD, we used the relative risk estimates from the meta-
analysis for incidence studies reported in Table 1 [3]. For two
individuals randomly chosen from different MD categories,
the expected log OR describing their difference in risk as a
pseudo-binary risk factor can be estimated by taking the
average of the log ORs, weighted by the prevalence of the
category. This weighted average from the meta-analysis
corresponds to an OR of 1.8, which suggests that the C-
statistic for a model with only MD would be expected to be
slightly higher than 0.6. As shown in Figure 1, to achieve a risk
prediction model that has a high concordance with actual risk,
it is necessary to take advantage of a set of risk factors whose
combined magnitude of effect corresponds to a high OR.
The Gail model
The most commonly used breast cancer risk prediction tool is
the Gail model [42,43]. This validated model is comprised of
six breast cancer risk factors, including age, age at menarche
(less than 12 years, 12, 13, 14 or more), age at first live birth
(nulliparous, less than 20 years, 20 to 24, 25 to 29, 30 or
more), number of first-degree relatives with breast cancer (0,
1, 2 or more), number of biopsies (0, 1, 2 or more), and
presence of atypical hyperplasia on a biopsy (yes or no). The
initial Gail model was based on a primarily Caucasian
population participating in the Breast Cancer Detection and
Demonstration Project (BCDDP) [42]. Later modifications to
this model included replacing the breast cancer incidence
rates from the BCDDP with estimates from the Surveillance,
Epidemiology, and End Results program, allowing for risk
estimates for African-American and Asian-American women
[43]. These modifications form the model that is known as the
Gail model 2 and are implemented in the National Cancer
Institute Breast Cancer Risk Assessment Tool [44]. Clinically,
this computerized model is used 20,000 to 30,000 times
each month to calculate a prediction of the absolute risk of
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Figure 1
Relationship between odds ratios (ORs) ranging from 1 to 1,000 and
C-statistic for binary risk factor and outcome. Vertical line represents
an OR of 1.5, which corresponds to the risk prediction possible using
a Gail model risk probability of 0.0167 as a binary cut point [46].breast cancer [45]. The Gail model 2 has been shown to be
well calibrated, with the predicted number of breast cancers
being nearly equal to the number of breast cancers observed
[43]. However, the C-statistic for the model is low and has
been estimated to be equal to 0.58 in an external validation
study [46]. Because of this modest concordance between
observed and predicted events, the Gail model is currently of
limited practical usefulness for obtaining risk estimates for
any given individual. Even so, it remains the most commonly
used tool for breast cancer risk prediction.
Incorporation of mammographic density into risk
prediction models
One approach to improve the precision of existing risk
prediction models is to incorporate other major risk factors.
Since MD is a strong risk factor with high population-
attributable risk [6], it is a likely candidate for addition to risk
prediction models. In fact, several studies have assessed the
contribution of a measure of MD to these models, including
the Gail model. The first of these examined the addition of the
BI-RADS measure of density to the original Gail model in a
multiethnic population [47]. In this study, the racial compo-
sition of the participants was more varied than in the original
study on which the Gail model was based. The authors also
built a simple model using only the BI-RADS measure, age,
and participants’ ethnicity which performed on a par with the
original Gail model in this study set. However, important
variables were not available for inclusion in the model. The
most notable of these is BMI, which is known to be highly
correlated with MD and whose inclusion has been shown to
strengthen risk estimates of MD [17]. Two additional studies
were performed to incorporate density into risk prediction
models. One of these was constructed with the intent of
providing a counseling tool at the time of mammography [48].
The model of Barlow and colleagues [48] was built using
participants who were seen at one of seven participating
centers in the National Institutes of Health Breast Cancer
Surveillance Consortium and incorporated the BI-RADS
density measure. The models were evaluated among
premenopausal and postmenopausal women separately;
besides BI-RADS density, the covariates included age, prior
breast procedure, and first-degree family history of breast
cancer for premenopausal women with the additional
covariates of Hispanic origin (yes/no), race, BMI, age at first
birth, current HRT, surgical menopause, and previous
mammographic outcome for postmenopausal prediction
models. Because the analyses were conducted on data
combined across centers, many of the covariates of interest
had a substantial degree of missing data, in particular on BMI.
In addition, the model of Barlow and colleagues was
developed and validated to predict 1-year risk and therefore
likely overemphasizes masked cancers and could overestimate
long-term risk. The third model to incorporate MD into a risk
prediction tool was a direct extension of the Gail model 2 [49]
constructed on the same BCDDP populations used in the
initial Gail model. Weight, rather than BMI, was available and
included in the model. Unlike in the two previous studies,
Chen and colleagues [49] employed the planimetry assess-
ment of MD (Table 1), which provided a quantitative and more
reproducible MD estimate on all mammograms. However,
mammograms were not available on all subjects in the
BCDDP; consequently, the number of subjects whose data
went into the estimation of the relative risk model was much
smaller than was available in the initial Gail model.
The results of these three models incorporating measures of
MD were similar: the addition of MD provided a significant
improvement to the risk prediction estimates, reflected by a
corresponding increase in the discriminatory accuracy of the
results. The increase in the C-statistic with the addition of
either the BI-RADS density [47,48] or percentage density
[49] was modest for every model (Figure 2) and ranged from
0.01 to 0.06. These three models also had limitations. First,
they were based on data collected from women who had
screening mammography and are limited in their evaluation of
women who are younger than mammogram age (generally
under 40). This is unfortunate as increased density is known
to be higher on average in the young, and risk prediction is
especially important at early ages when prevention efforts
may be most influential. Also, none of the populations had
complete covariate information (including BMI) and none has
been validated yet in other populations, which is essential
prior to their implementation in clinical practice. Finally, only
the BI-RADS and planimetry MD measures of density were
evaluated; the thresholding density measure, which also
allows for increased precision of the density estimate, has not
been considered to date.
Although the addition of MD shows promise for improving risk
prediction models, the information provided by these current
measures of MD improves the discriminatory power of risk
prediction models only incrementally. The application of risk
prediction models including MD will likely be preferred to the
existing Gail model, but even with MD, these models remain
limited in their ability to provide accurate individual estimates
of absolute risk. However, their use in targeting high-risk
groups on a population basis for the impact on modalities of
screening, intervals for surveillance, or preventive therapies or
strategies remains important.
Future directions for improvement in risk prediction
models with mammographic density
The current measurement of MD on a two-dimensional view
has proven to be robust in assessing breast cancer risk.
However, this assessment is not invariant to compression and
projection angle. Methods are now being developed that take
into account these factors and provide an estimation of the
volume of the fibroglandular tissue relative to the total breast
volume. These methods have been developed for digitized
mammograms and work best when reliable calibration data
(such as milliampere-second and peak kilovoltage) have been
collected with the mammogram [50-52]. With full-field digital
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matically, and recently several FFDM volumetric assessment
methods have been developed and validated [53,54].
Volumetric methods are expected to provide even stronger
breast cancer risk estimates than observed until now, as the
relative amount of fibroglandular tissue can be measured
more precisely.
In addition, change in MD (or volumetric density) may provide
improvement in risk prediction. Recent evidence illustrated
that changes in BI-RADS categories within women (which
coincide with substantial changes in percentage density) over
an average of 3 years of follow-up were associated with risk
[55]. This association was applicable only to women with
average (BI-RADS of 2) or high (BI-RADS of 3) density;
women with the highest density (BI-RADS of 4) remained at
greatest risk of breast cancer, and their risk did not decrease
with reductions in density, even when lowering their density
by three categories. Thus, multiple measures of MD could
also be important for predicting a woman’s risk.
Because breast cancer is a heterogeneous disease, it is likely
that there are different risk factors associated with subtypes.
As an example, estrogen receptor-positive/progesterone
receptor-positive (ER+/PR+) cancers appear to share a
different risk factor profile than ER–/PR– [56]. To date, the
limited data show MD as a risk factor in both ER+ and ER–
cancers (and likewise for PR+ and PR–) [57] and both in situ
and invasive cancers [58,59]. But there is the possibility that
MD is a stronger risk factor for cancers of certain histologic
subtypes (such as lobular cancers) or grade [60]. The ability to
predict breast cancer risk may then be improved when models
are used to predict specific subtypes of breast cancers.
Is mammographic density ready for prime time in risk
prediction?
If the risk prediction models that incorporate MD show
improved discrimination between cases and controls in
validation studies and across populations, they could readily
be incorporated into clinical practice and replace the existing
Gail model. However, the standardization of the MD measure
will be important to consider prior to their widespread use. Of
the three risk models that have incorporated MD to date, two
have used the BI-RADS density estimate and the other,
planimetry or tracing method (Table 1). The BI-RADS estimate
is currently assessed by most mammography clinics and could
easily be factored into the new risk models. However, the
quantitative MD estimates, such as the planimetry method,
require an experienced reader with ongoing training,
evaluation, quality control, and standardization across sites.
Fortunately, FFDM will allow for automated measures of both
area and volumetric density, which could provide highly
standardized measurements with appropriate calibration.
However, only 15% of mammogram units in the US are FFDM
[61], which speaks to the slow rate at which such MD
measures may be routinely available for risk models.
Although there is promise for improved risk prediction with
incorporation of MD, younger women who are not yet of
mammogram age (usually less than 40) will not reap the
benefits. These women are also those most likely to benefit
from improved risk assessment and targeted early prevention
strategies. With 30% of MD explained by known
epidemiologic risk factors [62] and 30% to 60% by genetics
[5,63], a large portion of variability in MD could be
understood. Thus, factors that explain MD, including both
classical risk factor and genetic information, could replace the
MD measure in risk models for younger women. Otherwise,
evaluation of younger women by cost-effective and lower
radiation alternative imaging modalities (such as a single-view
mammogram) or MRI is a potential option that could provide
an MD estimate for risk models in these women.
Summary
In this review, we have attempted to illustrate that MD is now
firmly established as a risk factor for breast cancer. The
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Figure 2
Gain in C-statistic in three breast cancer risk prediction models with the addition of mammographic density (MD). Studies refer to Tice and
colleagues [47], Barlow and colleagues [48], and Chen and colleagues [49]. Gail, Gail model; Gail 2, Gail model 2; Postmen Ext., postmenopausal
extended Gail model; Premen Ext., premenopausal extended Gail model.association with breast cancer risk is not the reflection of
masking bias and is independent of other breast cancer risk
factors. A few recent studies have incorporated aspects of
the mammogram into risk prediction models, with modest but
demonstrable improvements. As yet, none of these studies
has explored the potential contribution of the best quanti-
tative measures of MD. With additional calibration and
increasing use of FFDM in screening, it is possible to envision
clinical adoption of MD quantification in risk prediction
models. Given the evidence that the pathogenesis of breast
cancer likely begins early in life, prior to the age at which
mammography is recommended, additional risk prediction
approaches are likely necessary to broadly affect risk
reduction.
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